Peptides & Peptide Synthesis Products

Fmoc-Trp(Boc)-OH

Fmoc-Trp(Boc)-OH

$15.00
$15.00
Fmoc-Trp(Boc)-OH, Catalog No: 41012
Nα-Fmoc-N(in)-Boc-L-tryptophan, CAS: 143824-78-6, MW: 526.58, Formula: C31H30N2O6
Catalog No: 41012
Nα-Fmoc-N(in)-Boc-L-tryptophan, CAS: 143824-78-6, MW: 526.58, Formula: C31H30N2O6

* Required Fields

Description

Details

Nα-Fmoc-N(in)-Boc-L-tryptophan
Additional Information

Additional Information

Catalog Number 41012
CAS 143824-78-6
M.W. 526.58
Formula C31H30N2O6
IUPAC Name (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid
Synonym Nα-Fmoc-N(in)-Boc-L-tryptophan
Also Known As
  • (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid
  • (2S)-3-(1-tert-butoxycarbonylindol-3-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
  • (2S)-3-[1-(tert-butoxy-oxomethyl)-3-indolyl]-2-[(9H-fluoren-9-ylmethoxy-oxomethyl)amino]propanoic acid
  • (2S)-3-(1-tert-butoxycarbonylindol-3-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid
  • Fmoc-Trp(Boc)-OH
  • N(in)-Boc-Nalpha-Fmoc-L-tryptophan
  • Nalpha-Fmoc-N(in)-Boc-L-tryptophan
  • 47561_FLUKA
InChIKey ADOHASQZJSJZBT-SANMLTNESA-N
InChI InChI=1S/C31H30N2O6/c1-31(2,3)39-30(37)33-17-19(20-10-8-9-15-27(20)33)16-26(28(34)35)32-29(36)38-18-25-23-13-6-4-11-21(23)22-12-5-7-14-24(22)25/h4-15,17,25-26H,16,18H2,1-3H3,(H,32,36)(H,34,35)/t26-/m0/s1
SMILES CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C[C@@H](C(=O)O)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35
Cited Uses

Details

1. Varamini P et al, "Lipo-Endomorphin-1 Derivatives with Systemic Activity against Neuropathic Pain without Producing Constipation", PLoS ONE, 7(8) pp.e41909 ().
2. Tsai PC et al, "Stereoselective Hydrolysis of Organophosphate Nerve Agents by the Bacterial Phosphotriesterase", Biochemistry, 49(37) pp.7978-7987 (2010 Sep 21).
3. Schneider EL et al, "Positional Scanning Synthetic Combinatorial Libraries for Substrate Profiling", Methods in molecular biology (Clifton, N.J.), 539() pp.59-78 (2009).
4. Yamamoto T et al, "A Structure-Activity Relationship Study and Combinatorial Synthetic Approach of C-Terminal Modified Bifunctional Peptides That Are ?/? Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists", Journal of medicinal chemistry, 51(5) pp.1369-1376 (2008 Mar 13).
5. Linde Y et al, "Structure-Activity Relationship and Metabolic Stability Studies of Backbone Cyclization and N-Methylation of Melanocortin Peptides", Biopolymers, 90(5) pp.671-682 (2008).
6. Li Y et al, "Differentiation of chiral phosphorus enantiomers by 31P and 1H NMR spectroscopy using amino acid derivatives as chemical solvating agents", Tetrahedron, asymmetry, 18(12) pp.1391-1397 (2007 Jul 4).
7. Samant MP et al, "Structure-Activity Relationship Studies of Gonadotropin Releasing Hormone Antagonists Containing S-aryl/alkyl Norcysteines and their Oxidized Derivatives", Journal of medicinal chemistry, 50(9) pp.2067-2077 (2007 May 3).
8. Agnes RS et al, "Structure-Activity Relationships of Bifunctional Peptides Based on Overlapping Pharmacophores at Opioid and Cholecystokinin Receptors", Journal of medicinal chemistry, 49(10) pp.2868-2875 (2006 May 18).
9. Harris JL et al, "Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries", Proceedings of the National Academy of Sciences of the United States of America, 97(14) pp.7754-7759 (2000 Jul 5).
Reviews
cr